Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$105.67 USD

105.67
1,079,913

-0.78 (-0.73%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $105.69 +0.02 (0.02%) 7:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Mitchell Moore headshot

2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond

The marijuana industry is projected to grow at an annual rate of about 17% until it reaches $55.8 billion a year in 2025. The cannabis market has roughly tracked the S&P 500' s expansion in 2019 so far.

Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold

Mallinckrodt (MNK) beats on earnings in Q2 but marginally misses on revenues. The company suspends plan to spin-off the generic business for now.

Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates

Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y

United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.

Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised

Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.

Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y

Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.

Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up

Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.

Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.

Are Investors Undervaluing Novartis (NVS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y

Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.

Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?

Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis

Kinjel Shah headshot

Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus

J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.

Mark Vickery headshot

Top Research Reports for Abbott, Netflix & Philip Morris

Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Netflix (NFLX) and Philip Morris (PM).

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.

Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

Why Earnings Season Could Be Great for Novartis (NVS)

Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Merck's Antibiotic Recarbrio Gets FDA Nod for Infections

The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.

Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel

Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.

Mitchell Moore headshot

Should You Pick Up Novartis (NVS) Before Q2 Earnings?

Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.

Ekta Bagri headshot

Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?

Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.

Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA

The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.